The company specialises in developing small molecule treatments for liver diseases and infection. Among these drugs, Enanta has produced therapies to address respiratory syncytial virus (RSV), human metapneumovirus (hMPV) chronic hepatitis B virus (HBV) and focused R&D efforts for COVID-19 early into the pandemic.
The lawsuit claims Pfizer’s oral COVID-19 antiviral infringes on one of Enanta’s patents – patent 11,358,953 – and therefore seeks to claim damages from the company.
The patent in question covers “compounds and pharmaceutically acceptable salts which inhibit coronavirus replication activity, and methods of treating a coronavirus infection” and was awarded in early June…
